Mupirocin

• Description :

  Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae) . Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis[1][2][3][4][5][6].

• CAS Number :

  [12650-69-0]

• Product Name Alternative :

  BRL-4910A; Pseudomonic acid

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Aminoacyl-tRNA Synthetase; Antibiotic; Bacterial

• Type :

  Natural Products

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Endocrinology

• Assay Protocol :

  https://www.medchemexpress.com/Mupirocin.html

• Purity :

  98.34

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O)=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2

• Molecular Formula :

  C26H44O9

• Molecular Weight :

  500.62

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27 (4) :495-8.|[2]Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6 (10) :761-70.|[3]Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42 (3) :272-5.|[4]Twilley D, et al. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr 11;13:862112. |[5]Ha KR, et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118 (3) :535-40. |[6]Gilbart J, et al. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother. 1993 Jan;37 (1) :32-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  Launched